<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05025618</url>
  </required_header>
  <id_info>
    <org_study_id>2015-7-10-002</org_study_id>
    <nct_id>NCT05025618</nct_id>
  </id_info>
  <brief_title>Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma (ARTOME)</brief_title>
  <acronym>ARTOME</acronym>
  <official_title>Medico-economic Assessment of Adaptative Radiotherapy to Decrease Xerostomia in Locally Advanced Oropharynx Xerostomia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center Eugene Marquis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center Eugene Marquis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Standard treatment for oropharynx cancer is radiotherapy by intensity modulation with only&#xD;
      one planification before treatment. Adaptative radiotherapy integrates one or several&#xD;
      planifications during treatment radiotherapy in order to take into account anatomic&#xD;
      modifications that occurs.&#xD;
&#xD;
      Adaptative radiotherapy is very expensive, complex and is consuming human resources as well&#xD;
      as equipment.&#xD;
&#xD;
      ARTIX study (NCT01874587) entitled &quot;Phase III trial testing the benefit of&#xD;
      intensity-modulated radiotherapy with weekly replanifications versus intensity modulated&#xD;
      radiotherapy with only one planification in locally advanced oropharynx carcinoma for&#xD;
      decreasing xerostomia&quot; is completed and clinical data from this study are used to analyse if&#xD;
      xerostomia is decreased when adaptative radiotherapy is used.&#xD;
&#xD;
      ARTOME study will assess cost-efficiency and cost utility between standard treatment (one&#xD;
      pretherapeutic planification) and experimental treatment (weekly replanifications during&#xD;
      treatment). Clinical data from ARTIX study will be used for ARTOME study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 5, 2013</start_date>
  <completion_date type="Actual">December 8, 2020</completion_date>
  <primary_completion_date type="Actual">December 10, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cost utility analysis of standard radiotherapy (one pretherapeutic planification) compared to adaptative (weekly planification)</measure>
    <time_frame>2 years after end of radiotherapy treatment</time_frame>
    <description>The cost utility analysis is expressed in cost per one year life gained</description>
  </primary_outcome>
  <enrollment type="Actual">132</enrollment>
  <condition>Oropharynx Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated for oropharynx cancer in specialized hospitals&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Locally advanced non-metastatic carcinoma of the oropharynx limited to T3 and T4&#xD;
             (whatever the N) and N2-N3 (whatever the T)(AJCC stage III-IV)&#xD;
&#xD;
          -  Age ≥ 18 years and ≤ 75 years&#xD;
&#xD;
          -  Performance status (WHO ≤ 2)&#xD;
&#xD;
          -  Renal, hepatic and cardiovascular functions allowing systemic treatment administration&#xD;
&#xD;
          -  Adapted stomatologic care&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
          -  Membership or beneficiary of a national insurance scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Both parotids totally included in the target volume&#xD;
&#xD;
          -  Stages T1 or T2 with positive node disease N1&#xD;
&#xD;
          -  Neoadjuvant chemotherapy&#xD;
&#xD;
          -  Exereses of primitive tumor and/or nodes&#xD;
&#xD;
          -  History of other cancer within 5 years (except for basocellular epithelioma and&#xD;
             cervical)&#xD;
&#xD;
          -  Previous neck radiotherapy&#xD;
&#xD;
          -  Platinum salts, 5FluoroUracile (5FU) agents or cetuximab chemotherapy&#xD;
&#xD;
          -  Unstable diseases (cardiovascular, renal, pulmonary, systemic lupus or sclerodermia)&#xD;
             incompatible with study participation&#xD;
&#xD;
          -  Patient participating in other therapeutic trial with experimental drug, 30 days&#xD;
             before the inclusion.&#xD;
&#xD;
          -  Patient already recruited in another biomedical research ( non interventional study is&#xD;
             authorized)&#xD;
&#xD;
          -  Pregnant or breast feeding patients&#xD;
&#xD;
          -  Patient deprived of liberty, under tutorship, guardianship or placed under judicial&#xD;
             protection&#xD;
&#xD;
          -  Patient is deemed incapable of giving informed consent&#xD;
&#xD;
          -  Patients who, for family, social, geographic or psychological reasons, cannot be&#xD;
             adequately followed up and/or are incapable of undergoing regular controls.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renaud De Crevoisier, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Eugène Marquis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Claude Bernard</name>
      <address>
        <city>Albi</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur Lanroze</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLCC Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLCC Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLCC Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Milétrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLCC Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Tours - Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adaptative radiotherapy</keyword>
  <keyword>xerostomia</keyword>
  <keyword>medico-economic assessment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Xerostomia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

